US Herpes Simplex Virus Treatment Market Growth, Size, Trends, Competition and Future Outlook

US HSV1 Treatment Market Size- By Type, By Occurrence, By Treatment, By Route of Administration, By Population Type, By Gender, By Distribution Channel, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Q: How can I get a sample report on US HSV1 Treatment Market?

You can get the sample pages by clicking the link - Click Here

Published: Feb-2023	Report ID: HLCA2309	Pages: 1 - 103	Formats^*:
Category : Healthcare

US HSV1 Treatment Market Overview

According to SPER Market Research, the US HSV1 Treatment Market is estimated to reach USD 1.98 billion by 2032 with a CAGR of 12.13%.

Herpes Simplex Virus of the genitalia is the cause of the contagious condition known as genital herpes. The majority of those who have this infection either don't have any symptoms or only have minor ones. Small blisters that erupt and turn into ulcers in a specific location are typical signs. Also noticeable are flu-like symptoms like fever, aches, and swollen lymph nodes. Acyclovir and famciclovir are two medications used to treat genital herpes. These drugs aid in the prevention of herpes blisters and sores. Additionally, these medications can be used to treat genital herpes outbreaks and lessen subsequent problems.

The widespread use of genital herpes treatments will have a positive effect on the global market as a whole and considerably contribute to its expansion over the forecast period. During the forecast period, the genital herpes treatment market in emerging economies is expected to grow at a faster rate due to favourable government initiatives, an increase in healthcare spending, and increased awareness of the availability of a variety of genital herpes treatments for different patient groups.

Impact of COVID-19 on the US HSV1 Treatment Market

Covid-19 has a substantial impact on the market for treating genital herpes. Demand for commonly used medications like hydroxychloroquine has dramatically increased because of the need to treat COVID-19. The fact that there is such a large demand for these medications and that they are in such short supply in many affluent nations has created enormous prospects for makers of COVID-19 management medications. As a result of the demand for COVID-19 vaccines and medications to treat it, the pharmaceutical and biotechnology industries are predicted to develop significantly in the next years.

Get more information on this report: Download Free Sample PDF

Scope of the Report:

Report Metric	Details
Market size available for years	2019-2032
Base year considered	2021
Forecast period	2022-2032
Segments covered	By Type, By Occurrence, By Treatment, By Route of Administration, By Population Type, By Gender, By Distribution Channel, By End User
Regions covered	California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, Arizona, Colorado, Washington and Rest of the US.
Companies Covered	Abbott, Abcam plc., Agenus Inc., BIOMÃ‰RIEUX, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, GSK plc., Hologic Inc., Luminex Corporation, Maruho Co., Ltd., Merck KGaA, Meridian Bioscience, Inc., Norgen Biotek Corp., QIAGEN, Quidel Corporation, Sanofi, Teco Diagnostics, Thermo Fisher Scientific, Inc.

US HSV1 Treatment Market Segmentation:

1. By Type:

Cold Sores
Genital Herpes

2. By Occurrence:

Primary Herpes
Recurrent Herpes

3. By Treatment:

Drugs
Vaccines

4. By Route of Administration:

Oral
Topical
Parenteral

5. By Population Type:

Neonates
Paediatrics
Adults

6. By Gender:

Male
Female

7. By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

8. By End-User:

Hospitals
Specialty Clinics
Home Healthcare
Others

9. By Region:

California
Texas
Florida
New York
Pennsylvania
Illinois
Ohio
Georgia
North Carolina
Michigan
Arizona
Colorado
Washington and Rest of the US.

Key Topics Covered in the Report:

Size of US HSV1 Treatment Market (FYâ€™2019-FYâ€™2032)
Overview of US HSV1 Treatment Market
Segmentation of US HSV1 Treatment Market By Type (Cold Sores, Genital Herpes)
Segmentation of US HSV1 Treatment Market By Occurrence (Primary Herpes, Recurrent Herpes)
Segmentation of US HSV1 Treatment Market By Treatment (Drugs, Vaccines)
Segmentation of US HSV1 Treatment Market By Route of Administration (Oral, Topical, Parenteral)
Segmentation of US HSV1 Treatment Market By Population Type (Neonates, Paediatrics, Adults)
Segmentation of US HSV1 Treatment Market By Gender (Male, Female)
Segmentation of US HSV1 Treatment Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
Segmentation of US HSV1 Treatment Market By End-User (Hospital, Ambulatory centres, Others)
Statistical Snap of US HSV1 Treatment Market
Growth Analysis of US HSV1 Treatment Market
Problems and Challenges in US HSV1 Treatment Market
Competitive Landscape in the US HSV1 Treatment Market
Impact of COVID-19 and Demonetization on US HSV1 Treatment Market
Details on Recent Investment in US HSV1 Treatment Market
Competitive Analysis of US HSV1 Treatment Market
Major Players in the US HSV1 Treatment Market
SWOT Analysis of US HSV1 Treatment Market
US HSV1 Treatment Market Future Outlook and Projections (FYâ€™2019-FYâ€™2032)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPERâ€™s internal database
2.1.4 Premium insight from KOLâ€™s
2.2 Market size estimation

2.2.1 Top-down and Bottom-up approach

2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the US HSV1 Treatment Market

5. Market variables and outlook

5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTERâ€™S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Competitive Landscape

6.1 US HSV1 Treatment Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in US HSV1 Treatment Market

7. US HSV1 Treatment Market, By Type, 2019-2032 (USD Million)

7.1. Cold Sores
7.2. Genital Herpes

8. US HSV1 Treatment Market, By Occurrence, 2019-2032 (USD Million)

8.1. Primary Herpes
8.2. Recurrent Herpes

9. US HSV1 Treatment Market, By Treatment, 2019-2032 (USD Million)

9.1. Drugs
9.2. Vaccines

10. US HSV1 Treatment Market, By Route of Administration, 2019-2032 (USD Million)

10.1. Oral
10.2. Topical
10.3. Parenteral

11. US HSV1 Treatment Market, By Population Type, 2019-2032 (USD Million)

11.1. Neonates
11.2. Paediatrics
11.3. Adults

12. US HSV1 Treatment Market, By Gender, 2019-2032 (USD Million)

12.1. Male
12.2. Female

13. US HSV1 Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

13.1. Hospital Pharmacy
13.2. Retail Pharmacy
13.3. Online Pharmacy
13.4. Others

14. US HSV1 Treatment Market, By End-User, 2019-2032 (USD Million)

14.1. Hospitals
14.2. Specialty Clinics
14.3. Home Healthcare
14.4. Others

15. US HSV1 Treatment Market, By Region, 2019-2032 (USD Million)

15.1. US HSV1 Treatment Market Size and Market Share by Region (2019-2025)
15.2. US HSV1 Treatment Market Size and Market Share by Region (2026-2032)
15.3. California
15.4. Texas
15.5. Florida
15.6. New York
15.7. Pennsylvania
15.8. Illinois
15.9. Ohio
15.10. Georgia
15.11. North Carolina
15.12. Michigan
15.13. Arizona
15.14. Colorado
15.15. Washington
15.16. Rest of the US

16. Company Profiles

16.1. Abbott
16.1.1. Company details
16.1.2. Financial outlook
16.1.3. Product summary
16.1.4. Recent developments
16.2. Abcam plc.
16.2.1. Company details
16.2.2. Financial outlook
16.2.3. Product summary
16.2.4. Recent developments
16.3. Agenus Inc.
16.3.1. Company details
16.3.2. Financial outlook
16.3.3. Product summary
16.3.4. Recent developments
16.4. BIOMÃ‰RIEUX
16.4.1. Company details
16.4.2. Financial outlook
16.4.3. Product summary
16.4.4. Recent developments
16.5. Bio-Rad Laboratories, Inc.
16.5.1. Company details
16.5.2. Financial outlook
16.5.3. Product summary
16.5.4. Recent developments
16.6. DiaSorin S.p.A.
16.6.1. Company details
16.6.2. Financial outlook
16.6.3. Product summary
16.6.4. Recent developments
16.7. F. Hoffmann-La Roche Ltd
16.7.1. Company details
16.7.2. Financial outlook
16.7.3. Product summary
16.7.4. Recent developments
16.8. GSK plc.
16.8.1. Company details
16.8.2. Financial outlook
16.8.3. Product summary
16.8.4. Recent developments
16.9. Hologic Inc.
16.9.1. Company details
16.9.2. Financial outlook
16.9.3. Product summary
16.9.4. Recent developments
16.10. Luminex Corporation
16.10.1. Company details
16.10.2. Financial outlook
16.10.3. Product summary
16.10.4. Recent developments
16.11. Maruho Co., Ltd.
16.11.1. Company details
16.11.2. Financial outlook
16.11.3. Product summary
16.11.4. Recent developments
16.12. Merck KGaA
16.12.1. Company details
16.12.2. Financial outlook
16.12.3. Product summary
16.12.4. Recent developments
16.13. Meridian Bioscience, Inc.
16.13.1. Company details
16.13.2. Financial outlook
16.13.3. Product summary
16.13.4. Recent developments
16.14. Norgen Biotek Corp.
16.14.1. Company details
16.14.2. Financial outlook
16.14.3. Product summary
16.14.4. Recent developments
16.15. QIAGEN
16.15.1. Company details
16.15.2. Financial outlook
16.15.3. Product summary
16.15.4. Recent developments
16.16. Quidel Corporation
16.16.1. Company details
16.16.2. Financial outlook
16.16.3. Product summary
16.16.4. Recent developments
16.17. Sanofi
16.17.1. Company details
16.17.2. Financial outlook
16.17.3. Product summary
16.17.4. Recent developments
16.18. Teco Diagnostics
16.18.1. Company details
16.18.2. Financial outlook
16.18.3. Product summary
16.18.4. Recent developments
16.19. Thermo Fisher Scientific, Inc.
16.19.1. Company details
16.19.2. Financial outlook
16.19.3. Product summary
16.19.4. Recent developments

17. List of Abbreviations

18. Reference Links

19. Conclusion

20. Research Scope

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

How big is US HSV1 Treatment Market?

US HSV1 Treatment Market is projected to reach USD 1.98 billion by 2032, growing at a CAGR of 12.13% during the forecast period.

What is the growth rate of US HSV1 Treatment Market?

US HSV1 Treatment Market grew in market size from 2021. The Market is expected to reach USD 1.98 billion by 2032, at a CAGR of 12.13% during the forecast period.

What is the anticipated CAGR of the US HSV1 Treatment Market during the forecast period?

US HSV1 Treatment Market CAGR of 12.13% during the forecast period.

How can I get a sample report on US HSV1 Treatment Market?

You can get the sample pages by clicking the link - Click Here

What is the market size of the US HSV1 Treatment Market ?

US HSV1 Treatment Market size is USD 1.98 billion from 2022 to 2032.

Which segment is expected to lead the US HSV1 Treatment Market ?

US HSV1 Treatment Market Segment is Covered By Type, By Occurrence, By Treatment, By Route of Administration, By Population Type, By Gender, By Distribution Channel, By End User

Which region is expected to have the highest market share in US HSV1 Treatment Market?

The North America region is anticipated to have the highest market share in US HSV1 Treatment Market.

Who are the key players in US HSV1 Treatment Market ?

The key players in the market include Companies Covered Abbott, Abcam plc., Agenus Inc., BIOMÉRIEUX, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, GSK plc., Hologic Inc., Luminex Corporation, Maruho Co., Ltd., Merck KGaA, Meridian Bioscience, Inc., Norgen Biotek Corp., QIAGEN, Quidel Corporation, Sanofi, Teco Diagnostics, Thermo Fisher Scientific, Inc.

What is the conclusion of the US HSV1 Treatment Market?

During the forecast period, the genital herpes treatment market in emerging economies is expected to grow at a faster rate due to favourable government initiatives, an increase in healthcare spending, and increased awareness of the availability of a variety of genital herpes treatments for different patient groups.